Skip to main content
Figure 1 | Trials

Figure 1

From: Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

Figure 1

Trial design of the ELATE trial. All patients are screened for eligibility and the patients who suit the criteria are randomized in an equal ratio to either the octreotide monotherapy arm or the octreotide and everolimus arm. All patients receive a CT scan at baseline and after 12 months of treatment. Control visits are performed at 2, 6, 12, 24, 36 and 48 after baseline.

Back to article page